Co-Diagnostics (LTS:0A50) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A50 Co-Diagnostics Inc LTS:0A50
63 GF Score
Price $1.52
GF Value $2.17
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0A50
63GF Score
Co-Diagnostics Inc LTS:0A50
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Co-Diagnostics (LTS:0A50) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of $1.52 is trading 30% below its estimated GF Value™ of $2.17. GuruFocus considers Co-Diagnostics to be Possible Value Trap.

Key valuation signals for LTS:0A50:

  • FFO:
  • GF Value™: $2.17 vs. price of $1.52 (30% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the LTS:0A50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for LTS:0A50

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price
$2.17
GF Value